Fig. 1.

In vivo effects of miR-203 treatment on PyMT mice, started at tumor onset and sustained for two weeks. A Schematic of the doxycycline (Dox) treatment (in green) schedule in vivo, on miR-203 wild-type or miR-203 knock-in; PyMT mice, during two weeks from tumor onset (before the tumors are detected by micro-CT). B Representative micro-CT images of mice subjected to Dox treatment (in the figures, “control” indicates miR-203 wild-type; “miR-203” indicates knock-in mice), after Dox treatment (12 weeks of age) and at the endpoint (18 weeks of age). C Number of tumors per mouse at the endpoint, in control and miR-203-treated mice. D Final tumor volume of control and miR-203-treated mice. In C, D, data are represented as mean ± s.d. (Number of mice and total number of tumors per group are indicated in the figure.) E Left panel, Illustrative hematoxylin and eosin (H&E) and Ki67 immunohistochemistry (IHC) staining of control and miR-203-treated tumors at the endpoint. Right panel, Violin plot showing the quantification of Ki67 staining, six different fields from three independent tumor samples were analyzed. Scale bar, 500 µm. ****p < 0.0001; ** < 0.01; *p < 0.05 (Student’s t test)